The Latest Breaking News from Johnson & Johnson (

More than 40 years after the unexpected deaths of seven people due to tainted medicine, Tylenol became the centre of attention again for a different reason.

Johnson Johnson (NYSE:JNJ) on Friday announced that an investigational immune-based induction regimen with Tecvayli (teclistamab) and Darzalex Faspro (daratumumab and hyaluronidase) demonstrated meaningful clinical efficacy in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM).

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson Johnson's (NYSE:JNJ) Inlexzo (gemcitabine intravesical system) as a new treatment approach for certain types of bladder cancer patients who need additional options following unsuccessful BCG therapy and for patients refusing or ineligible for bladder removal surgery (radical cystectomy).

Johnson Johnson (NYSE:JNJ) on Tuesday won regulatory approval for its drug delivery product Inlexzo to treat high-risk non-muscle invasive bladder cancer, a milestone Goldman Sachs says could launch “a powerful new product cycle” for the company's TAR-200 program.

Johnson Johnson (NYSE:JNJ) reported new cardiovascular data at the 2025 European Society of Cardiology Congress.

Johnson Johnson (NYSE:JNJ) on Thursday shared topline data from the Phase 2a DAISY proof-of-concept study evaluating the combination of nipocalimab with an anti-tumor necrosis factor alpha (anti-TNFα) therapy in rheumatoid arthritis (RA) patients with refractory disease.

Johnson & Johnson has significantly outperformed other healthcare stocks over the past year, and analysts remain moderately bullish on the stock’s prospects.

As the healthcare sector lags broader markets, AbbVie’s innovation in immunology and Johnson & Johnson’s MedTech expansion make these dividend giants standout bargains at below-market valuations

Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.